DiaSorin (OTCMKTS:DSRLF) Shares Gap Up – Should You Buy?

DiaSorin S.p.A. (OTCMKTS:DSRLF)’s share price gapped up before the market opened on Friday . The stock had previously closed at $74.25, but opened at $81.90. DiaSorin shares last traded at $80.25, with a volume of 3,100 shares traded.

Analyst Ratings Changes

Several analysts have commented on DSRLF shares. Piper Sandler assumed coverage on shares of DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. Deutsche Bank Aktiengesellschaft lowered shares of DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, June 17th. BNP Paribas Exane cut DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th. Zacks Research upgraded DiaSorin to a “hold” rating in a report on Tuesday, May 12th. Finally, UBS Group lowered shares of DiaSorin from a “buy” rating to a “neutral” rating in a research report on Thursday, April 9th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

DiaSorin Price Performance

The company’s 50-day simple moving average is $74.81 and its 200-day simple moving average is $76.23.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.